Lianidou: Points to this '12 PLoS One https://t.co/O8dKmLJJLw mentions Adna method commercialized by QIAGEN. #MDxE16
9:27am April 5th 2016 via Hootsuite
Lianidou: Shared a figure from this '14 review in introduction: https://t.co/QmP17jdrAb #MDxE16
9:25am April 5th 2016 via Hootsuite
Lianidour: Adv of qPCR - can multiplex, can use with WGA for DNA mutation. Also can use for miRNA, methylation. Easy to design too. #MDxE16
9:24am April 5th 2016 via Hootsuite
Lianidour: Their focus is qPCR-based assays for CTC analysis. CTC-spec expression, devoid in leukocytes. #MDxE16
9:21am April 5th 2016 via Hootsuite
Evi Lianidour (Athens Greece): Dev, validation and clinical applications of molecular assays for the mol characterization of CTCs #MDxE16
9:20am April 5th 2016 via Hootsuite
Q: How to simulate a vein? Chen: Spiked cells into buffer and used a roller-bottle to simulate #MDxE16
7:06am April 5th 2016 via Hootsuite
Chen: Showed WGA of single CTCs using a new 'catch and release' method. Ongoing pt enrollment for high-risk prostate ca #MDxE16
7:04am April 5th 2016 via Hootsuite
Chen: Use a CellCollector 'wire' to show first specificity of selection on VCaP cell line, shows data for enrichment, lysis, qPCR #MDxE16
6:56am April 5th 2016 via Hootsuite
Chen: Used mRNA visualized in single CTCs via padlock probes and RCA '12 ref https://t.co/nX3ETsxmOM to look for AR-V7 #MDxE16
6:52am April 5th 2016 via Hootsuite
Chen: Consistent numbers w/Pantel's group. Showed pan-CK pos image, neg for CD45. All PSA neg #MDxE16
6:49am April 5th 2016 via Hootsuite
Chen: Their cutoff: 1 CTC or greater. 21% pos by CellSearch n=48, 40% by CellCollector n=53. Range: 1 to 15 cells Median: 1 cell #MDxE16
6:48am April 5th 2016 via Hootsuite
Chen: Reviews project - high-risk prostate ca, PSA >20, Gleason >8. CellSearch, EpiSpot, GILUPI CellCollector #MDxE16
6:45am April 5th 2016 via Hootsuite
Shukun Chen (Univ Graz Austria): A functionalized medical device for CTC isolation in vivo and single CTC molecular analysis #MDxE16
6:42am April 5th 2016 via Hootsuite
Q: Any non-tumor cells in CSF? Faure: Puncture may involve some cells, looked very closely for potential contamination, not observed #MDxE16
6:38am April 5th 2016 via Hootsuite
Faure: Concludes w/research potential - new Rx targets and understanding blood/brain barrier dynamics of metastasis #MDxE16
6:36am April 5th 2016 via Hootsuite
Faure: Potential to use earlier in clinical eval; also question remains of prognostic significance of CTM-like aggregates in CSF #MDxE16
6:35am April 5th 2016 via Hootsuite
Faure: For lung ca, n=18 figure shown from '15 ref https://t.co/rMgqun98qL #MDxE16
6:34am April 5th 2016 via Hootsuite
Faure: Sequential analysis fig from '12 BMC ref https://t.co/kMPuRsxEmD at different time points #MDxE16
6:31am April 5th 2016 via Hootsuite
Faure: Spec: no contaminating cells; sens: all established LM pts detected, quantitated. 1 to >10K cells. #MDxE16
6:29am April 5th 2016 via Hootsuite
Faure: Valerie Harper, US actress, affected by LM HuffPost article: https://t.co/MqeQ5lUfxt #MDxE16
Faure: Mainly lumbar punctures; CellSearch and cytology and biochemistry (classical techniques). Est or suspected LM #MDxE16
6:28am April 5th 2016 via Hootsuite
Faure: CSF volume from 10.5mL 97% pos. '94 ref https://t.co/JrGcsn9ugH >120 samples, 4d between samples/study 5mL vol #MDxE16
6:26am April 5th 2016 via Hootsuite
G. Faure (CHU NancyFrance): Quant of malignant cells in CSF w/Cellsearch Veridex improves Dx and mgmt of carcinomatous meningitis #MDxE16
6:24am April 5th 2016 via Hootsuite
Visit @SeraCare at #MDxE16 Molecular Diagnosis Europe during the bread or at lunch for reference material info https://t.co/RCgaWVVIPX
6:06am April 5th 2016 via Hootsuite
Q: Is the future in France for general testing? Lohmann: Still not reimbursed, hopeful by end of this year. 1/250 cutoff vs 1/1000 #MDxE16
5:38am April 5th 2016 via Hootsuite
Lohmann: @SeraCare information here: https://t.co/a0ehhC5Ann #MDxE16
5:37am April 5th 2016 via Hootsuite
Lohmann: Thus they can measure risk as a function of cutoff, the lower FF the more impt measuring variability in process #MDxE16
5:36am April 5th 2016 via Hootsuite
Lohmann: Wanted different fetal fractions, down to 4% (their threshold). Z-score close to 3 cutoff. At 1% FF, impt variability #MDxE16
5:35am April 5th 2016 via Hootsuite
Lohmann: Shows data for cutoff by Z-score, where the T21, T18, T21 in comparison to normal distribution of Z-scores. Clear diff #MDxE16
5:34am April 5th 2016 via Hootsuite
Lohmann: Pt observed fetal fractio shown at 11%; Seraseq is at 12%; five runs; showed clear highly pos Z-scores #MDxE16
Lohmann: Sample to final report needs control; also need to be 'as close as possible to biological sample'. #MDxE16
5:32am April 5th 2016 via Hootsuite
Lohmann: Uses two issues: is a normal plasma pool an acceptable control? Also no positive control for process. #MDxE16
5:31am April 5th 2016 via Hootsuite
Lohmann: Their validation work published here: https://t.co/BOWNGeHGWb #MDxE16
Lohmann: French regulation: must have accreditation (ISO 15189 COFRAC auth) #MDxE16
5:29am April 5th 2016 via Hootsuite
Lohmann: Offered since Nov '13; tech transferred from SQNM. Sens/Spec boht >99.9% non-report <1% #MDxE16
5:28am April 5th 2016 via Hootsuite
Lohmann: Aneuploidy testing: 811K births in France/y; CERBA does 6.5K NIPT of 13.4K tests/y #MDxE16
Lohmann: CERBA founded in '67; leader in clinical pathology; >500 employees; 53K tests/d. clin pathology, genetics/cyto #MDxE16
5:27am April 5th 2016 via Hootsuite
Laurence Lohmann (Lab CERBA) Implementation of Serasq aneuploidy reference materials for non-invasive prenatal testing #MDxE15
5:25am April 5th 2016 via Hootsuite
Van Vooren: Recent '15 ref https://t.co/Io03OgU59y n=1350 #MDxE16
5:24am April 5th 2016 via Hootsuite
Van Vooren: Shows segmental aneuploidies, K Rudd (Emory) data presented at #ACMG16 also plan on #ESHG16 in a few months #MDxE16
5:20am April 5th 2016 via Hootsuite
Van Vooren: Presents OneSight analysis (Cartagenia); shows segmental aberration, trisomy, complex rearrangements #MDxE16
5:19am April 5th 2016 via Hootsuite
Steven Van Vooren (Agilent) 'Seeing is knowing, introduction to OneSight' #MDxE16
5:17am April 5th 2016 via Hootsuite
Q: Long-term culture and cp GEX to primary? Alix-Panabieres: 4d culture analysis, 6m, 1y: similar to 'what we looked for' #MDxE16
4:58am April 5th 2016 via Hootsuite
Alix-Panabieres: Now testing DEPArray, also Parsortix for size and deformability, combining enrichment w/culture. Cellcollector too #MDxE16
4:56am April 5th 2016 via Hootsuite
Alix-Panabieres: Kept all plasma, now looking at ctDNA and cf-miRNA in exosomes. Refers to CANCER-ID participation. #MDxE16
4:55am April 5th 2016 via Hootsuite
Alix-Panabieres: Soon after, Annals Oncol ref stated PD-L1 in primary is rare. Explains potential causes - micrometastases, Ab-spec #MDxE16
4:53am April 5th 2016 via Hootsuite
Alix-Panabieres: Moving onto PD-L1: '15 Mol Oncol ref https://t.co/fBIXOXRij6 Using CellTracks and Rarecells platforms #MDxE16
4:52am April 5th 2016 via Hootsuite
Alix-Panabieres: Indicated CTC numbers via CellSearch; what was special about this pt? 1st relapse v high number #MDxE16
4:47am April 5th 2016 via Hootsuite
Alix-Panabieres: Shows individ pt w/met colon ca, first line Rx, and two relapses; lines produced at several points 1/140 pts #MDxE16
Alix-Panabieres: CTC line stable now for 3y; E-M phenotype; induces in vitro angiogenesis. Can do in vivo, in vitro drug tests #MDxE16
4:45am April 5th 2016 via Hootsuite
